AfyaIndex
Kenyan Reference & Directory
Free lookups: 0/3 Unlock Pro
Clinical reference Find a medicine
Ctrl K
Drug categories Interaction checker
0 of 3 free lookups remaining Upgrade
New search Medicine profile Vildagliptin / Metformin
Check interactions

Clinical medicine profile

Vildagliptin / Metformin

Biguanide antidiabetic

POM
Evidence state Source not available Reviewed 14 Aug 2026
Route
ORAL
Schedule
POM
ATC
Not assigned
PPB status
registered
Patient advice Check interactions
Verification required

This profile needs source confirmation

A traceable source link is not attached to this profile. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.

01 Risk first

Safety essentials

The information most likely to change a prescribing or dispensing decision.

Contraindications

  • [From component Metformin] Diabetic comma
  • severe renal impairment
  • hepatic impairment
  • keto-acidosis
  • cardiac failure
  • excessive alcoholic intake
  • pancreatitis
  • severe infections and trauma
  • pregnancy and lactation
  • dehydration
  • pre-desposition to lactic acidosis
  • conditions associated with hypoxaemia

Precautions

  • [From component Metformin] Discontinue 2-3 days before surgery
  • conditions causing dehydration
  • infections
  • low calorie diet
  • monitor vitamin B12 annually
  • patients to be stabilized in hospital when combination therapy is used.
02 Point of care

Dosing matrix

Population and organ-function guidance, shown together for faster comparison.

Adult

Dosing is indication-, age-, weight- and organ-function-specific for this INN. Do not use class averages for high-risk patients. Confirm the exact regimen in the current SmPC and Kenya Standard Treatment Guidelines. Typical professional workflow: (1) confirm indication, (2) check renal/hepatic function, (3) screen interactions/allergies, (4) select dose/route/duration, (5) define monitoring.

Paediatric

Paediatric dosing is weight- and age-based; use a paediatric formulary / SmPC. Do not extrapolate adult tablets without calculation.

Renal

Dose by eGFR; stop if severe impairment or acute kidney injury.

  • CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Hepatic

Avoid in significant hepatic impairment (lactic acidosis risk).

03 Clinical use

Use, effects & interactions

Indications

  • Therapeutic use is agent- and indication-specific within the class (Biguanide antidiabetic).
  • Use according to culture results, national guidelines (Kenya STG/EML where applicable) and the current product SmPC.

Adverse effects

  • [From component Metformin] Lactic acidosis in presence of renal failure
  • nausea and vomiting
  • anorexia
  • diarrhoea
  • metallic taste
  • urticaria
  • decreased vitamin B12 absorption.

Drug interactions

Open multi-drug checker ↗
  • [Vildagliptin] First-line type 2 diabetes pharmacotherapy in most guidelines unless contraindicated.
  • Educate on sick-day rules.
  • Review eGFR at least annually or more if CKD. [Metformin] First-line type 2 diabetes pharmacotherapy in most guidelines unless contraindicated.
  • Educate on sick-day rules.
  • Review eGFR at least annually or more if CKD.
04 Pharmacology

Mechanism & disposition

Combination product.

Combination product.Component mechanism (Metformin): A biguani…Metformin decreases hepatic gluconeogenesi…
Read complete mechanism

Combination product. Component mechanism (Metformin): A biguanide that acts by de-creasing gluconeogenesis and by increasing peripheral metabolism of glucose. Metformin decreases hepatic gluconeogenesis, improves peripheral insulin sensitivity, and reduces intestinal glucose absorption. Does not stimulate insulin secretion — low intrinsic hypoglycaemia risk alone.

Onset

Days for glycaemic effect

Duration

Taken daily chronically

Route

ORAL

Absorption

saturable. Not metabolised; renally excreted unchanged. Accumulation in renal impairment drives lactic acidosis risk. [Metformin] Oral absorption saturable. Not metabolised; renally excreted unchanged. Accumulation in renal impairment drives lactic acidosis risk.

05 Special populations

Pregnancy, lactation & diet

Pregnancy

[Vildagliptin] Increasingly used in GDM/PCOS pathways per specialist protocols; insulin remains standard in many settings. [Metformin] Increasingly used in GDM/PCOS pathways per specialist protocols; insulin remains standard in many settings.

Lactation

Generally considered compatible.

06 Kenya market

Brands & loaded prices

From—
Median—
Listings10
BrandManufacturerPackObserved price
Galvusmet tablets 50/500mg Novartis Pharma Services Inc Tablet 500mg Unavailable
Galvusmet tablets 50/1000mg Novartis Phrma Services Inc Tablet 1000mg Unavailable
GLUCOWELL-MET 50 Not recorded 850MG TABS 28*S UnavailableDaima Chemist price-list reference
GLUCOWELL-MET 50:1000MG FILM COATED TABLETS COSMOS LIMITED Film-Coated Tablet 1000MG Unavailable
VILDAGOOD M ZAIN PHARMA LIMITED Tablet Unavailable
VILDAMET 100mg XR/500mg XR TABLETS M/s. Innocia Lifesciences Pvt. Ltd. Film-Coated Tablet 100mg Unavailable
VILDAMET 100mg XR/850mg XR TABLETS M/s. Innocia Lifesciences Pvt. Ltd. Tablet 100mg Unavailable
VILDAMET 100mg XR/1000mg XR TABLETS M/s. Innocia Lifesciences Pvt. Ltd. Film-Coated Tablet 100mg Unavailable
Vilget-M 50mg & 500mg Tablets Getz Pharma (Pvt.) Limited Film-Coated Tablet 50mg Unavailable
Vilget-M 50mg & 1000mg Tablets Getz Pharma (Private) Limited Film-Coated Tablet 50mg Unavailable
07 Provenance

Sources & review state

Primary sourceLocal active-ingredient clinical extract; Component monographs (multi-source pipeline); Professional class pharmacology (Biguanide antidiabetic)
Last reviewed14 Aug 2026
EvidenceSource not available

Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.